In previously untreated recurrent/metastatic PD-L1-positive head and neck squamous cell carcinoma, adding danvatirsen to pembrolizumab did not improve response rate (15.6% vs 14.3%; P = 1) in 66 treated patients; adverse events were more frequent (97.8% vs 85.7%).
RCTn = 69
Saba et al. Danvatirsen plus Pembrolizumab versus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): A Randomized, Phase II Trial